International Flavors & Fragrances (IFF) Barclays 17th Annual Global Consumer Staples Conference summary
Event summary combining transcript, slides, and related documents.
Barclays 17th Annual Global Consumer Staples Conference summary
22 Jan, 2026Leadership and strategic vision
CEO brings 42 years of experience in chemical and biological industries, emphasizing innovation and sustainability.
Focus on building a company that delivers short-term results while preparing for growth in 2025 and beyond.
Commitment to providing guidance that is achievable under reasonable scenarios.
Shift to an end-to-end business model, empowering business units with full accountability.
Executive team alignment and clarity in decision-making are prioritized.
Financial performance and guidance
Achieved two consecutive quarters of solid growth, with Q3 off to a strong start.
Volume growth guidance for the year is 3%-5%, with Q3 expected up 4% and Q4 flat.
Guidance assumes low end-market growth and reflects market uncertainties.
Productivity improvements and selective cost-cutting support performance.
Business segment updates and portfolio strategy
Functional ingredients pricing adjusted after previous overpricing led to lost business; now using targeted, market-aligned pricing.
Portfolio optimization underway, focusing on high-value, innovation-driven segments and evaluating commoditized areas for long-term fit.
Consumer fragrances show double-digit growth, while fine fragrances have slowed to mid-single digits due to tougher comparisons.
Management changes and renewed focus have energized the scent division.
Latest events from International Flavors & Fragrances
- Disciplined execution, portfolio focus, and strong governance drove 2025 progress and value creation.IFF
Proxy Filing18 Mar 2026 - Shareholders can vote on annual meeting proposals online or virtually by April 28, 2026.IFF
Proxy Filing18 Mar 2026 - Transformation, innovation, and disciplined execution drive growth and margin expansion.IFF
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - Adjusted EBITDA rose 7% on 2% currency-neutral sales growth, with major divestitures and $1.15B goodwill impairment.IFF
Q4 202512 Feb 2026 - Adjusted EBITDA up 22% and full-year guidance raised on strong volume and margin gains.IFF
Q2 20242 Feb 2026 - Strong Q3 growth and raised 2024 outlook driven by volume recovery and margin gains.IFF
Q3 202416 Jan 2026 - Strong 2024 growth and margin gains; 2025 outlook tempered by FX and divestitures.IFF
Q4 20248 Jan 2026 - Biotech innovation and disciplined strategy drive strong results and future growth potential.IFF
Consumer Analyst Group of New York Conference 20257 Jan 2026 - Directors elected, auditor ratified, and executive pay approved; CEO pay structure discussed.IFF
AGM 202525 Dec 2025